CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%
Home/Business/Akums Drugs Q1FY27 Profit Surges 57.55%,…

Akums Drugs Q1FY27 Profit Surges 57.55%, Stock Jumps

Business
By ThePip Desk•
Add as a preferred source on Google
Akums Drugs Jumps 5.70% on 57.55% Consolidated Net Profit Surge in Q1FY27

Infographic: Akums Drugs Jumps 5.70% on 57.55% Consolidated Net Profit Surge in Q1FY27

Key Highlights

Akums Drugs & Pharmaceuticals reports a strong 57.55% rise in Q1FY27 consolidated net profit to Rs 100.01 crore, driving its stock up 5.70%. Discover financial highlights.

Akums Drugs & Pharmaceuticals saw its stock climb 5.70% to Rs. 736.20 on the , propelled by a substantial 57.55% increase in its consolidated net profit for the first quarter ended June 30, 2026 (Q1FY27).

The company reported its Q1FY27 financial results, showcasing significant growth in its consolidated performance compared to the previous year’s corresponding quarter.

Financial Highlights Q1FY27

  • Consolidated : Rs 100.01 crore, marking a 57.55% jump from Rs 63.48 crore in Q1FY26.
  • Consolidated : Rs 1,197.01 crore, an increase of 13.92% from Rs 1,050.76 crore in Q1FY26.

Conversely, the standalone results presented a different picture, with a marginal decline in net profit for the same period.

Performance Q1FY27

  • Standalone Net Profit: Rs 44.84 crore, a marginal fall of 0.07% from Rs 44.87 crore in Q1FY26.
  • Standalone Total Income: Rs 418.38 crore, up by 15.90% from Rs 361.00 crore in Q1FY26.

The stock opened at Rs. 717.25 and reached an intra-day high of Rs. 750.00, with 50875 shares traded on the counter.

Market Activity & Shareholding

  • Current Trading Price: Rs. 736.20, up 39.70 points.
  • Previous Closing Price: Rs. 696.50.
  • : Rs. 750.00 (August 10, 2026).
  • : Rs. 410.10 (January 21, 2026).
  • Current : Rs 11411.06 crore.
  • Holding: 75.26%.
  • : 15.35%.
  • Non-Institutional Holding: 9.39%.

Akums Drugs & Pharmaceuticals’ robust consolidated earnings for Q1FY27 were the primary driver behind its positive stock movement, despite a slight dip in standalone net profit.

Akums DrugsIndia